Pipeline
| Project | Category | Target / Indications | 2023 | 2024 | 2025 | 2026 | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AT-03 | Best-in-class | CLDN6 |
|
|||||||||||||||||||||||||||||||||
| AT-06 | Only-in-class Bispecific-ADC | To be disclosed |
|
|||||||||||||||||||||||||||||||||
| AT-00 | Next Generation of HER2-ADC | HER2 |
|
|||||||||||||||||||||||||||||||||
| AT-04 | First-in-class | ALPPL2 |
|
|||||||||||||||||||||||||||||||||
| AT-01 | Dual Payloads | ROR1 |
|
|||||||||||||||||||||||||||||||||
Our leading assets were presented during the AACR 2024 Annual meeting:
1.Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Drug Conjugates
Session Date and Time: Monday Apr 8, 2024, 1:30 PM – 5:00 PM
Location: Poster Section 21
Poster Board Number: 19
Published Abstract Number: 3138
Compared with a benchmark ADC in clinical development, AT65474 shows stronger binding, higher internalization, superior in vitro cytotoxicity, and stronger bystander killing effect. When evaluated in PA-1 and OV90 xenograft models of ovarian cancer, AT65474 displays significantly higher efficacy over the benchmark ADC.
2.Development of AT2604, a highly efficacious ADC targeting alkaline phosphatases ALPP and ALPPL2
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Drug Conjugates
Session Date and Time: Monday Apr 8, 2024, 1:30 PM – 5:00 PM
Location: Poster Section 21
Poster Board Number: 18
Published Abstract Number: 3137
AT2604 displayed strong tumor growth inhibition (>90%) at 1 mg/kg (QW3x2 dosing) in both mouse xenograft models of gastric (NCI-N87) and pancreatic (HPAC) cancer models. Furthermore, a pre-tox study in non-human primates concluded AT2604 is well-tolerated in NHP up to 10 mg/kg (QW3x3 dosing) and did not exhibit any non-reversible adverse effects; implying that AT2604 possesses an improved safety profile over other vedotin-based ADCs. Taken together, the data supports the continued development of AT2604 towards evaluation in human trials.
3.Discovery of AT86474, a highly efficacious Anti-ROR1 ADC utilizing a proprietary payload
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Technologies and New Inhibitors
Session Date and Time: Monday Apr 8, 2024, 9:00 AM – 12:30 PM
Location: Poster Section 22
Poster Board Number: 2
Published Abstract Number: 1858
AT86474 was evaluated in a preclinical CDX mouse model of ovarian cancer, where substantial tumor growth inhibition was observed with two weekly doses at as low as 1 mg/kg. As ROR1 over-expression is also observed in many solid tumors, such as pancreatic, gastric, breast and lung cancers, the use of AT86474 can be expanded to benefit a large patient population.
Email us at contactus@axcynsis.com if you are interested to learn more about our Pipelines and Leading assets.